New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > LEU CML - daSATinib > LEU - daSATinib 100
This regimen is a component of LEU CML - daSATinib

daSATinib 100 (LEU CML - daSATinib)

Treatment Overview

Chronic phase treatment - give continuously until disease progression or unacceptable toxicity.

Cycle 1 (and all further cycles) - 30 days

Cycle length:
30

Cycle details

Cycle 1 (and all further cycles) - 30 days

Medication Dose Route Days Max Duration
daSATinib 100 mg Once daily oral administration 1 to 30

Full details

Cycle 1 (and all further cycles) - 30 days

Day: 1

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 2

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 3

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 4

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 5

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 6

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 7

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 8

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 9

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 10

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 11

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 12

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 13

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 14

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 15

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 16

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 17

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 18

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 19

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 20

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 21

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 22

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 23

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 24

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 25

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 26

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 27

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 28

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 29

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Day: 30

Medication Dose Route Max duration Details
daSATinib 100 mg Once daily oral administration
Instructions:

Swallow whole, do not crush or chew with a large glass of water. Take at the same time each day. Grapefruit or grapefruit juice may interact with this medicine. Discuss with your pharmacist.

Supportive Care Factors

Factor Value
Emetogenicity: Minimal to low
Tumour lysis syndrome prophylaxis: Tumour lysis syndrome prophylaxis may be considered

Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.

References

Kantarjian H, Shah NP, Hochhaus A. et al. 2010 " Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia". N Engl J Med. Jun 17;362(24):2260-70., PMID: 20525995

Cortes, J. E., G. Saglio, H. M. Kantarjian, et al. 2016. "Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial." J Clin Oncol 34(20):2333-2340., PMID: 27217448

Shah, N. P., F. Guilhot, J. E. Cortes, et al. 2014. "Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study." Blood 123(15):2317-2324., PMID: 24569263

Jabbour, E. and H. Kantarjian. 2016. "Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring." Am J Hematol 91(2):252-265., PMID: 26799612

Apperley JF, Cortes JE, Kim DW et al. 2009 " Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. " J Clin Oncol. Jul 20;27(21):3472-9., PMID: 19487385

Kantarjian H, Cortes J, Kim DW et al. 2009 " Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up."Blood. Jun 18;113(25):6322-9., PMID: 19369231

Hehlmann R. 2012. "How I treat CML blast crisis". Blood. Jul 26;120(4):737-47., PMID: 22653972

Saglio G, Hochhaus A, Goh YT et al. 2010 " Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily". Cancer. 2010 Aug 15;116(16):3852-61., PMID: 20564086

Fox, L. C., K. D. Cummins, B. Costello, et al. 2017. "The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia." Blood Adv 1(13):802- 811., PMID: 29296724

Ross, D. M., C. Arthur, K. Burbury, et al. 2018. "Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors." Intern Med J 48 Suppl 2:5-13., PMID: 29388307

Breccia, M., A. Salaroli, M. Molica, et al. 2013. "Systematic review of dasatinib in chronic myeloid leukemia." Onco Targets Ther 6:257-265., PMID: 23569389

Bristol-Myers Squibb (NZ) Limited Sprycel New Zealand Datasheet 15 February 2022 https://www.medsafe.govt.nz/profs/datasheet/s/Spryceltab.pdf (Accessed 29 March 2022).

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.